Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Antengene to Participate in Three Upcoming Investor Conferences in May/June 2022-05-06 08:30
Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting 2022-04-29 22:30
Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018 2022-04-27 08:30
Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022-04-11 08:30
Antengene's Pivotal "MARCH" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine 2022-04-06 20:03
Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes 2022-03-30 09:00
Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates 2022-03-18 22:12
Antengene Announces IND Approval in China for the Phase I Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma 2022-03-10 08:52
Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting 2022-03-09 20:00
Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma 2022-03-09 19:08
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications 2022-03-02 08:47
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037 2022-02-07 08:30
Antengene to Present at the 40th Annual J.P. Morgan Healthcare Conference 2022-01-05 12:50
Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors 2021-12-30 09:51
First Patient Dosed in Australia in ATG-101 First-in-Human Trial 2021-12-20 11:01
First Patient Dosed in Australia in ATG-101 First-in-Human Trial 2021-12-20 10:56
Antengene Announces NDA Approval by NMPA for XPOVIO®, China's First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma 2021-12-17 22:27
Antengene and XtalPi Announce AI-Driven R&D Collaboration 2021-12-16 16:30
Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting 2021-12-14 18:00
Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors 2021-12-13 08:30
1 2 3 4 5 6 7